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Abstract 
In the pharmaceutical industry, enhanced process understanding resulting in superior 
control of product attributes, has the potential to save up to 20 % of process engineering 
and product development costs during drug development. With the aim of achieving 
enhanced process understating, a novel approach for granulation of fine powders is 
presented. First, a mould with the desired particle shape and size is created using 3D 
printing followed by casting using elastomeric material. The formulation is prepared through 
wet massing and tested as a thin film on flat elastomeric membranes. The thin film itself can 
be a product but it also gives a good indication of coating performance before coating the 
patterned elastic membrane with the formulation i.e., 3D printed elastic mould granulation. 
Results show that following granulation and drying, granules of controlled size and shape 
(e.g. cubic and 500 μm), strength, friability and flowability can be formed. The method 
presented may allow for more robust process development in particle engineering. 
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1. Introduction 
Size enlargement process is defined as any process where small particles are agglomerated, 
compacted, or otherwise brought together into larger, relatively permanent masses in 
which the original particles can still be distinguished. The result is a somewhat porous and 
irregular structure of particles bonded together (Ge et al., 2018). In this study, the terms of 
size enlargement and granulation are used interchangeably. Size enlargement is often 
mechanistically modelled as three distinct rate processes  which occur simultaneously: (1) 
wetting and nucleation, (2) coalescence and growth, and (3) attrition and breakage (Litster 
and Ennis, 2004). Granulation is employed to improve the properties of a powder mixture: 
enhanced flowability, dissolution, compression and compaction characteristics, uniformity 
of drug distribution, product appearance; inhibit segregation and dusting (Shinde et al., 
2014; Cantor et al., 2008). Due to these favourable advantages, granulation is used to make 
granules in the range of 50 μm to 50 mm in food, detergents (Rahmanian et al., 2016), 
catalysts, pesticides, plastics, fertilisers, metalliferous ores, nuclear fuels, ceramics, c arbon 
black, cement kiln feeds and pharmaceuticals (Ennis et al., 2008; Capes and Darcovich, 
1997). 
Granulation is normally categories into two groups: wet and dry granulation. Wet 
granulation is conventional, at least in the pharmaceutical industry, where it is estimated to 
be used for approximately 80 % of the cases (Shinde et al. 2014). Wet granulation is defined 
as modifying particle structure and morphology through the use of liquid acting on the 
powder blend to form inter-particulate bonds which then result in granules of varying sizes 
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(Cantor et al., 2008). Wet granulation technologies include high shear, low shear (Cantor et 
al., 2008), fluidised bed (Passerini et al., 2010) and twin screw extrusion (Khorsheed et al., 
2018). The advantages of wet granulation include a versatility in formulations, reduced 
binder quantity, short processing times, ability to process highly cohesive materials, 
predictable end point determination to list a few (Cantor et al., 2008). Disadvantages 
consists of and are not limited to a significant loss of material during dispending and drying, 
labour intensive tasks, long drying times, difficulty in scale up and a lack of mechanistic 
understanding despite years of experience (Suresh et al., 2017). 
Dry granulation is an unconventional technology that can be subdivided into two categories: 
roller compaction and slugging (Guigon et al., 2007). Roller compaction is by far the most 
commonly used technique in dry granulation. It is desirable due to the absence of water 
which is attractive for drugs which are moisture/heat sensitive, its fitness for continuous 
processing, high drug loading (70-100%) and flexibility in volume of production. The 
problems with roller compaction include a lack of mechanistic understanding, susceptibility 
of dusting, loss in compactability and limited applicability (Bindhumadhavan et al., 2005). 
Alternative granulation technologies consist of: steam granulation, moisture activated dry 
granulation, pneumatic dry granulation, thermal adhesion granulation process, foamed 
binder technologies and freeze granulation technology (Shinde et al., 2014; Shanmugam, 
2015). Generally the new technologies are able to produce granules with a good 
reproducibility in shorter processing times. They can also be environmentally friendly with 
few variables to optimise and lower operating costs. However, there are some recurring 
problems such as lack of holistic process understanding, high risk exposure to potent API, 
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high capital costs and large equipment foot-print. There are also new challenges such as a 
lack of regulatory framework (Shinde et al., 2014; Shanmugam, 2015). 
Additive manufacturing, also known as 3D printing, has recently been gaining traction in 
research and development in a wide variety industries and process technologies like 
granulation (Bandyopadhyay and Bose, 2015; Chua and Leong, 2015; Ge et al., 2017,2018). 
This is because the patents recently expired in circa 2010 allowing hobbyists and the like to 
take full advantage of 3D printing’s extremely high flexibility in design e.g., unique 3D net-
shape with high strength-to-weight ratio (Thompson, 2007). Some key challenges 3D 
printing has yet to overcome include high capital cost and relatively long operating times for 
high volume manufacture (Bandyopadhyay and Bose, 2015). In this work it is used for 
prototyping, as is normally the case (Thompson, 2007), but recently 3D printing has been 
applied to granulation (Ge et al., 2017,2018) and other solid and/or liquid oral dosage forms 
(Genina et al., 2017). Ge et al. (2017,2018) were able to use 3D printing to substantially 
improve current knowledge on the third rate process, attrition and breakage. 
One of the strong points about the work by Ge et al. (2017,2018) is that the granules have 
consistent shape and properties so more conclusive conclusions can be made based on 
these features. As a 3D printing technology method, the Ge et al. (2017,2018) method 
suffers from the common challenge of high volume production. As far as the authors are 
aware, no granulation methods have been presented where prototype granules can be 
made before transferring to mature technologies like polymer injection moulding and 
extrusion where high volume manufacture can be achieved. This is because the produced 
granules are normally too complex for transfer to other process technologies. 
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Nemaura Pharma Ltd.’s (henceforth: NPL) process  for granulation is very different compared 
to the other processes presented. The process is also known as 3D printed elastic mould 
granulation (3DEMG). NPL’s manufacturing method consists of the formation of a film on a 
substrate and then stretching the substrate along one or more axes to fracture the film into 
particle structures. The substrate may be moved continuously along a production line as the 
film is formed followed by stretching through acceleration. The substrate may contain 
elevated structures patterned in such a manner as to control the fracturing of the film 
(Chowdhury, 2015).  
NPLs process may be much more capable in producing granules that are within size 
specification and may be similar enough to current granules to produce on pilot or full 
industrial scale within a relatively short timescale. The aim of this work is to produce and 
control the properties of granules by producing them using 3DEMG. This is done by 
producing granules using 3DEMG followed by characterisation of critical granule properties.  
2. Experimental 
2.1 Materials 
Ibuprofen Grade 40 supplied by SI Group (Schenectady, USA) was used as the API. The bulk 
density was 0.33 g/mL. As stated in the European Medicines Agency (EMA) guidelines, 
purified water is to be used as the liquid medium (Gohlke and Doke, 2014). Aqueous 
solutions of sugars and synthetic polymers were used as the binding agents: sucrose (Fisher 
Scientific, UK), anhydrous-glucose, fructose (Acros Organics, USA), sorbitol (Calbiochem, 
USA), polyvinyl pyrrolidone K90 (PVP) (VWR, UK), polyethylene glycol 4000 (PEG) (Sigma 
Aldrich, UK). Non-ionic surfactants were also used as wetting agents: Kolliphor P 407 (BASF, 
Germany), Tween 20 (Acros Organics, USA). Silicone adhesive and silicone oil for casting 
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were both supplied by Techsil (Warks, UK). Silicone (manufactured by Silex, UK), parafilm 
(manufactured by Bermis, UK) and 3M 9776 polyethylene single sided foam medical tape 
(henceforth: pink foam) (manufactured by 3M, UK) were used as substrates. A saline 
phosphate buffer (PBS) supplied by (AppliChem, Germany) was used as the 
disintegration/dissolution medium. 
2.2 Equipment 
The manual film applicator (manufactured by Gradco, USA) uses a knife head coating 
configuration. The films are dried using a 25L vacutherm vacuum oven (manufactured by 
Thermo Scientific, UK). SolidWorks 2016 CAD software and Objet30 Prime (manufactured by 
Stratasys) were used for 3D printing. The substrates were stretched using Hoffmann type 
pinchcocks of 50 mm bandwidth (manufactured by VWR, UK). Tensometer (manufactured 
by Mecmesin, UK) was used to measure the strain energy of substrates  and for strength 
testing. The tensile tester was fitted with an upper and lower punch with outer diameters of 
13.5 mm. Tensile grips of 10 mm width were also used for strain energy measurements. 
British standard sieves (manufactured by Endecotts, UK) and an Axioskope 40 optical 
microscope equipped with an Axiocam (manufactured by Zeiss, UK) were used for granule 
characterisation. A UC152D stir-hot plate (manufactured by Stuart, UK) was used for 
disintegration/dissolution testing.  
2.3 Methodology 
3DEMG is the combination of wet agglomeration (Hapgood and Smith, 2015) with a 
modified transdermal patch manufacturing process (Ghosh et al., 1997). In this case an 
elastic substrate is used in place of a rigid substrate. In this study 3DEMG is used to fabricate 
either films for sublingual/buccal administration or discrete granules of controlled size and 
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shape for capsules/tablets. Part of the methodology involves analysis of formulation 
performance during film application because this is theorised to be linked to performance of 
3DEMG. As shown later, the formulation of the substrate is identical but surface features 
differ. Therefore, for example, a consistently strong attachment of thin-film to substrate 
after stretching is hypothesised to result in strong attachment of formed granules to the 
substrate after stretching. 
The desired granule size and shape is selected when designing the master mesh. As shown 
in Figure 3, the master mesh is designed on SolidWorks. The mesh in Figure 1 shows that the 
desired particle size and shape can be 500 μm and cubic while Figure 2 shows that the 
desired particle size and shape can be cuboid. Figure 4 shows that the mesh is then printed 
using the Objet30 Prime. Figure 5 shows that to obtain the elastic polymer membrane, 
silicone adhesive and silicone oil are casted onto the master meshes in a ratio of 10:1 
(adhesive: oil) with the maximum substrate thickness being limited by the height of the 
mesh. 
The first step of 3DEMG is to mix the API with excipients. This can be done in a batch, semi-
batch or continuous set-up. In this study the mixing was done in a batch set-up using a 
scintillation vial and spatula. The Ibuprofen was passed through a 1 mm sieve before mixing. 
Ibuprofen was selected as a model compound as the crystals are needle-like exhibiting poor 
flowability (i.e. cohesive) (Qu et al., 2017), brittle fracture, dusting, segregation and a 
tendency of lumping together (Le et al., 2006). Therefore, the effectiveness of 3DEMG can 
be assessed. During the mixing, unless otherwise stated, the composition of each mixture is 
given in Table 1. A liquid content of 75% was chosen for wet massing as it was deemed an 
adequate amount for ease of application of the formulation on the substrates while 
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maintain a satisfactory drug loading of 25% API. It is important to note that when the sugar 
solutions were combined with the API to form slurries/pastes they showed characteristics 
similar to pseudoplastic fluids (Chhabra, and Richardson, 2011). 
After mixing, the formulation is then placed on the substrate followed by application or 
alternatively, application and mould filling using the film applicator left-to-right (LTR). The 
landing areas on the substrate are then cleaned off using the film applicator right-to-left 
(RTL). The formulation is dried using the vacuum oven forced convection set-up – vacuum 
pump is turned-on and the air-inlet is left slightly open. To separate the granules from the 
substrate, the substrate is stretched to 30 % elongation using Hoffmann pinchcocks and 
released instantly. As a result of the stored strain energy being released instantly, the 
granules are dislodged from the mould. The separation is conducted in a closed chamber 
fitted with a looking glass in order to contain the propelled granules. 
As implied earlier, a consistently strong attachment of thin-film to substrate after stretching 
is hypothesised to result in poor solid-solid separation of formed granules after stretching. 
Consequently, similar to what is shown in Table 2, a number of binders are tested at 
different solid concentrations and film thicknesses before selecting a binder for granulation. 
As an example, the formulations which performed well were tested up to 9 times for 
sorbitol 60% solution and 4 times for PVP 20% solution. 
2.3.1 Granule characterisation 
The granule size distribution has been characterised by sieve analysis. A series of 3 British 
Standard (BS) test sieves (200, 400, 1000μm) were stacked and vibrated manually for 5 
minutes. Granule shape was characterised by optical microscopy. The friability was 
determined using one BS standard sieve of 1 mm for granules greater than 1 mm, 0.4 mm 
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for 1.0 mm granules and 0.2 mm for 0.5 mm granules; following the method presented by 
Birch and Marziano (2013) using two minutes per cycle. Three experimental runs per 
granule size were done for sieving and a single run was done per granule size for friability. 
Flowability measurements were done using the angle of repose method of Copley Scientific 
(2016) which, with the exception of the protruding outer lip, adheres to European 
Pharmacopoeia Chapter 2.9.36 and US Pharmacopeia Chapter <1174> on Powder Flow. The 
base had a fixed diameter of 23.5 mm. Each flowability measurement was taken three 
times. 
The granule strength has been characterised by the quasi-static side crushing test method 
(Rahmanian and Ghadiri, 2013). The individual granules are compressed between two 
punches using the tensile testing machine. In order to obtain some statistics, at least 10 
granules were tested per sample. The exact procedure for this method is described by ASTM 
Standard D4179 (1982), Ryu and Saito (1991) and Couroyer et al. (2000). Typical force–
displacement data when agglomerates break have been presented by Walker et al. (1997). 
The tensometer was also used for measurement of silicone substrate strain energies. A cut 
out of 80 mm by 10 mm samples of substrates are clipped onto the tensometer. They are 
then stretched at the same set rate of 10 mm/min until 30 % elongation is reached. As 
illustrated in Equation 1 (Hamper, 2009), this produces a straight-line force-displacement 
curve that can be used to calculate the strain energy. 
The bioavailability of a drug is determined by its dissolution over time. Before dissolution of 
the drug occurs, the granule and/or tablet must undergo wetting and disintegration (Smrčka 
et al.,2016). Disintegration testing was done by placing 20 mg granules per 4g PBS solution 
of pH 7.4. Disintegration end-point of the starting material was done by visual inspection. 
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E = ½Fx = ½kx2     (1) 
Where, E is elastic strain-energy, F is force, x is displacement and k is the stiffness constant.  
3. Results and discussion 
3.1 Formulation studies 
3.1.1 Effect of binder selection 
The studied sugars included sucrose, glucose, fructose and sorbitol. As shown in Figures 6 to 
9, all sugars appear to exhibit an acceptable level of adherence to the silicone substrate 
during the application as formed films had an aspect ratio (width/length) much greater than 
1/15. The synthetic polymers included PEG and PVP. In the selection of binders health and 
safety is the vital consideration. The sugars are usually cariogenic except for sorbitol in this 
case, while the polymers are essentially non-toxic as they are not absorbed in the 
gastrointestinal tract or mucous membranes (Rowe et al.,2013; Hartwig, 2013). PEGs are 
practically not volatile so PEG 4000 formulations were not studied further (Hartwig, 2013). 
For PVP in order to adhere to the chosen substrates the binder content tends to be much 
higher than the usual and processing of such viscous solutions is cost intensive. Therefore, 
sugars are probably more suitable for the chosen process.  
Figure 6 illustrates that the films formed using fructose solutions have an aspect ratio much 
greater than 1/15 but were unable to dry in a reasonable time (less than 18 hours). Figure 7 
displays films formed using glucose which, upon drying, stuck onto the substrate strongly 
and this is unsuitable for processing. Figure 8a shows films formed using sucrose which dry 
in in less than 18 hours while undergoing crystallisation during solidification. Figure 8b 
shows that when dried, the films underwent multiples fractures but remained attached to 
the substrate so solid-solid separation becomes challenging. On the other hand, films 
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formed using sorbitol, as shown in Figure 9, are much easier to remove from the substrate. 
Like sucrose films, they also dry in less than 18 hours and undergo multiple fractures. In the 
light of these results, sorbitol formulations were used for the study. 
3.1.2 Effect of binder concentration 
The binder concentration affects the process performance in a number of ways. A generally 
high binder content leads to creating a more cohesive network of all ingredients (see Figures 
10a, 11a and 12a) (Cantor et al., 2008). Low binder concentrations appear to be undesirable 
where binders are the only excipient. For PVP, it is clear from Figure 10b that during film 
application the formulation displays a poor adherence to the foam substrate. Figure 14 
shows a low binder concentrations of a sugar (40 %wt sucrose) which lead to a significant 
increase in drying times greater than 18 hours. Figures 12b,c and 13a show high binder 
concentrations (30 %wt PVP) also appear to be undesirable as inconsistent films are more 
likely to be produced.  
Figure 8b (60 %wt sucrose) and Figure 11b (20 %wt PVP) show that there seems to be an 
optimum binder concentration where suitable adherence to substrate, consistent film 
thickness and acceptable drying times are observed. As an increased binder concentration 
leads to enhanced binding it was important to study whether disintegration of the films was 
still possible. In the case of PVP, this was not a concern as it is usually used to enhance the 
dissolution of poorly soluble drugs (Rowe et al., 2013). As highlighted in Table 6, it was 
determined that the disintegration generally occurs in less than 5 minutes. Maintaining a 
short disintegration time of less than 5 minutes for high binder concentrations, is desirable 
as it may lead to high strength granules and tablets that are able to disintegrate/dissolve a s 
wanted. 
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3.1.3 Effect of surfactant addition 
Surfactants may act as detergents, wetting agents, emulsifiers, foaming agents, and 
dispersants (Porter and Porter, 1991). In this case non-ionic surfactants were used as 
wetting agents so that a lower concentration of binder may be used. As shown in Figures 15 
and 16 the adherence to substrate was modified by the use of Tween 20 but drying of the 
films did not occur in less than 18 hours. Tween 20 is liquid in standard conditions so this is 
to be expected. When the poloxamer P 407 was used foaming of the formulation occurred 
which is unwanted for film application i.e., poor control of film and probably granule 
properties. 
3.1.4 Effect of silicone casting composition 
Two formulations were tested. One with high silicone oil content (10:1 of silicone adhesive: 
silicone oil) and one with low silicone oil content (20:1 of silicone adhesive: silicone oil). It 
was found that high silicone oil content led to a more rigid material so this meant that for a 
given strain, more strain energy is stored for separation of the granules from the substrate.  
In addition, silicone moulds made using the 20:1 ratio are able to remain rigid during the 
mould filling process, maintaining the desired structure of the formulation being casted. 
However, Figure 20 and Equation 1 support the decision of selecting the 10:1 ratio as the 
elastic mould becomes stiffer with increasing thickness . Therefore a thick substrate with 
20:1 silicone adhesive-to-oil ratio may be too stiff to stretch to 30 % elongation. 
3.2 Process studies 
3.2.1 Effect of substrate material properties 
Both of the materials used for this study, silicone and parafilm, are hydrophobic. Parafilm is 
especially hydrophobic having a contact angle of 103°±11° with water and a RMS roughness 
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of ~ 60 (50 x 50 μm2) as presented by Yamaguchi et al. (2016) and Ping et al. (2009). In the 
case of silicone (polysiloxane), it is generally hydrophobic having a high contact angle with 
water. However, silicone can undergo surface treatment/hydrophilisation to increase its 
wettability with water (Roth et al., 2008). In this study the silicone did not undergo chemical 
treatment. 
When stretched, parafilm does not return to its original length while silicone quickly returns 
to its original after release. This means that the energy is dissipated during elongation for 
parafilm while it is mainly stored as strain energy for silicone. Therefore, parafilm would be 
unsuitable for a continuous manufacturing process. Furthermore, as shown in Figures 11b 
and 17, due to parafilms surface properties the ability of a formulation to adhere on the 
substrate homogeneously is poorer than with silicone. While the film of the same 
formulation contracts inwardly for parafilm (see Figure 17), it effectively coats silicone (see 
Figure 11b). 
As shown in Figures 10b and 12c there are cases where pink foam was coated with silicone 
to create a substrate with the combination of two elastic constants. This was to prevent the 
applied formulation from leaking through the pink foam. Solid-solid separation would 
probably be different as the strain energy storage and dissipation would probably be 
different for pink foam-silicone as compared with the pure silicone. Further studies are 
required to investigate this in the future. 
3.2.2 Effect of film thickness and substrate thickness 
The film thickness of the PVP formulation is 500 μm in Figure 11 and 200 μm in Figure 18. In 
Figure 11, when it is stretched to 30% elongation, the film is delaminated from the substrate 
while multiple fractures occur in Figure 18. The same phenomena occurred with the sorbitol 
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formulation. Figure 19 shows that at a thickness of 300 μm it delaminated while Figure 9c 
shows that at a film thickness of 100 μm multiple fractures occurred. Hence, there may be a 
critical film thickness/range of film thickness values for which either multiple fractures or 
delamination occurs. The distinction between multiple fractures and delamination is 
probably also a function of solid-liquid content. 
The parafilm membrane thickness was always 127 μm as it was purchased from the vendor 
(Bermis, UK). On the other hand, the silicone was casted in house so the thickness of the 
polymer membrane could be varied. As expected, Figure 20 shows an increase in the 
thickness of a silicone membrane appears to result in a stiffness constant. The smallest 
thickness casted was 300 μm while the largest thickness was 6.0 mm. 
3.2.3 Effect of patterned surfaces 
By patterning an elastomer via moulding one can obtain granules of desired size and shape. 
In this study two types of surface/moulding patterns were explored: cuboid and cubic. In 
addition to the cubic granules, cuboid moulds were made to illustrate the versatility in size 
and shape control with elastic mould granulation. Figures 21 and 23c show cuboid granules 
of 0.5 mm, 1.0 mm and 5.0 mm width while, Figures 22, 23, 25 show cubic granules of 0.5 
mm, 1.0 mm, 2.0 mm and 4.0 mm size. Figure 23 shows that if the landing areas on the 
surface of the substrates are not cleaned-off effectively, agglomeration of the granules may 
occur due to formation of solid bridges (Okeyo et al., 2017). It is postulated that off-
specification size is owing to incomplete mould filling (Kalpakjian and Schmid, 2006) and/or 
agglomeration of granules during drying (Litster, 2016) due to incomplete land area 
cleaning. 
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Figures 24 and 25 show that optical microscopy and sieving have been used to check that 
the granules produced are very similar to the size and shape of the elastic mould. The cubic 
shape was selected as it is easy to mould and it exhibits good flowability (Carr, 1965) using 
the categories from the US Pharmacopeia (see Table 3) (Hoag and Lim, 2016; Pharmacopeia, 
2005). Brittle fracture is the most common failure mode for pharmaceutical granules but, 
for the tested sorbitol formulation, strength testing revealed that the granules appear to 
undergo relatively slow irreversible deformation. Figure 26 and 27 display trends similar to a 
force-displacement curve at the onset of plastic deformation as presented by Zhou and Qiu 
(2010). Plastic deformation is desirable as it leads to high strength tablets (see Table 4) 
(Shiraishi et al., 1994, 1995). However, it is important to note that the cuboid granules 
exhibit multiple fractures on the long axis (see Figure 21c) and slow irreversible deformation 
on compression. 
Assuming perfect mixing, the granules are 36 %wt Ibuprofen and 64 %wt sorbitol. Ibuprofen 
is susceptible to brittle fracture but as it is not the majority of the formulation, the granules 
are more characteristic of sorbitol (Shariare, 2012). Li et al. (2013) show that sorbitol 
deforms plastically so it is safe to assume that this is why the granules are deforming slowly 
and irreversibly during compression. Figure 28 displays data from friability tests which show 
that in some cases a less than 1 %wt of material is lost and this is desirable for inhibiting 
dust formation (see Table 5). The low Agglomerate Brittleness Index (ABI) values also 
indicate the granules are hard (Birch and Marziano, 2013). Disintegration tests displayed in 
Table 6 also showed that granules are able to disintegrate in less than 5 minutes despite 
their high strength. 
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Another detail worth mentioning is that the drying time of patterned substrates is 
significantly longer than the drying time of thin films. This is most likely to due to the mass 
transfer limitations introduced by reduction in effective surface area in contact with air, and 
increase in thickness of the formulation. Succinctly, the drying step is currently the rate 
limiting step. Preliminary studies have shown that one may be able to significantly reduce 
the drying time by reducing the liquid content and increase the binder concentration of the 
formulation. 
3.2.4 Effect of stretching 
Stretching the substrate resulted in either fracture or delamination of thin films. However, 
in the case of patterned surfaces, it only separated the surface of the granules from the 
surface of the polymer membrane. For the granules to be fully separated from the substrate 
the stretched membrane had to be released instantly to propel the granules out of the 
substrate i.e., strain energy solid-solid separation. The effect of strain energy on solid-solid 
separation is presented in Figure 29. Excluding the anomalous point at 66 mJ of strain 
energy, there appears to be a positive correlation between strain energy and solid-solid 
separation. This was hypothesised to be the case. Similar to Figure 20, a wider range or 
more data point measurements of strain energy would have to be made before statistical 
regression is undertaken.  
4. Conclusion 
A novel approach for the formation of API loaded films and granules is presented in order to 
attend to much needed solutions to some of the existing problems in formulation 
engineering: structural control, process understanding and continuous processing. NPL’s 
process offers a platform for small scale experiments, ease of scale-up and smaller 
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equipment footprint owing to continuous processing, as well as particulate structural 
control to produce granules of controlled size, shape, strength, friability and flowability. It is 
also important to note that NPL’s process is not a solution to all the problems as it is 
unsuitable for moisture sensitive APIs. Overall NPL’s process has the potential to either 
replace traditional technologies or compete as an alternative. 
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Figure 1. Cubic desired particle design and size with (A) 500 μm to 5000 μm length (B) 500 
μm to 5000 μm length (C) 500 μm to 5000 μm length and (D) 1.5 mm to 15 mm.  
Figure 2. Cuboid desired particle design and size with (A) 500 μm to 5000 μm length and (B) 
500 μm to 5000 μm length. 
Figure 3.SolidWorks CAD model of (a) 500 x 500 x 500 μm cubic pattern (b) 1 x 1 x 80 mm 
cuboid pattern both (a) and (b) are on 50 x 80 mm master meshes. 
Figure 4. 3D print of master meshes from Figure 1a (left) and 1b (right). 
Figure 5. Silicone moulds of master meshes from Figure 1a (left) and 1b (right). 
Figure 6. Ibuprofen-fructose 70% solution. 
Figure 7. Ibuprofen-glucose 40% solution (a) applied (b) stretched. 
Figure 8. Ibuprofen-sucrose 60% solution (a) optical microscopy (b) applied (c) stretched. 
Figure 9. Ibuprofen-sorbitol 60% (a) optical microscopy (b) applied (c) stretched. 
Figure 10. Ibuprofen-PVP 10% solution (a) optical microscopy (b) applied. 
Figure 11. Ibuprofen-PVP 20% solution (a) optical microscopy (b) applied (c) stretched. 
Figure 12. Ibuprofen-PVP 30% solution. 
Figure 13. Ibuprofen-sucrose 80% solution (a) applied (b) stretched. 
Figure 14. Ibuprofen-sucrose 40% solution. 
Figure 15. Ibuprofen (20.8 % wt)-PVP 2% (62.5% wt)-Tween 20 (16.7 % wt). 
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Figure 16. Ibuprofen (19.2 % wt)-PVP 10% (57.7 % wt)-Tween 20 (23.1 % wt). 
Figure 17. Ibuprofen-PVP 20% solution on flat parafilm (a) light coating (b) heavy coating. 
Figure 18. Ibuprofen-PVP 20% solution (200 μm) (a) applied film (b) subsequently stretched 
membrane and fractured film. 
Figure 19. Ibuprofen-Sorbitol 60% Solution (300 μm) 
Figure 20. Graph of effect of substrate thickness on strain energy. 
Figure 21. Cuboid granules (a) 0.5 mm (b) 1 mm (c) 5.0 mm. 
Figure 22. Cubic granules 0.5 mm, 1.0 mm, 2.0 mm, 4.0 mm LTR. 
Figure 23. Effect of cleaning (a), (b) without surface cleaning (c), (d) with surface cleaning.  
Figure 24. Size distribution of cubic granules (a) 1000 μm (b) 500 μm. 
Figure 25. Optical microscopy of cubic granules (a) 1000 μm (b) 500 μm.  
Figure 26. Force-displacement graphs for ten 1000 μm cubic granules of ibuprofen-sorbitol 
60 % solution. 
Figure 27. Force-displacement graphs for ten 500 μm cubic granules of ibuprofen-sorbitol 
60% solution. 
Figure 28. Friability testing. 
Figure 29: Effect of strain energy on solid-solid separation. 
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Table 1. Formulation composition for mixing. 
Compound Mass (g) % Weight Comments 
Ibuprofen 0.5 25  
Binder Solution 1.5 75 See Table 2 
Total 2.0 100  
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Table 2. Formulation composition for preparation of binder solutions (example). 
Compound Mass (g) % Weight Comments 
Sorbitol Binder 6.0  60 Heat up to 80°C and 
hold for 30 min while 
agitating at 3/9 
Purified water 4.0 40 
Total 10.0 100 
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Table 3. Effect of 3DEMG on flowability of granules. 
Compound Angle of Repose (°) Comments 
Ibuprofen Grade 40 63 ± 1 Very Poor Flowability 
1000 μm Cubic Granules 31 ± 4 Good Flowability 
500 μm Cubic Granules 42 ± 4 Passable – may hang up 
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Table 4. Maximum normal stress experienced by granules. 
Compound Normal Stress (MPa) Equation 
500 μm Cubic Granules 160 Normal Stress = Force/Area 
1000 μm Cubic Granules 40 
5000 μm Cubic Granules 1.6 
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Table 5. Friability risk categories. (Birch and Marziano, 2013) 
Extent of Structural Integrity Classification Recommendation 
<10 % Mass Loss Low Acceptable formulation 
10 %< Mass Loss <20% Intermediate Slight or no modification 
Mass Loss >20 % High Change formulation 
Agglomerate Brittleness Index Classification Recommendation 
< 0.1 ABI or ABI= 0 Low Acceptable formulation 
0.1< ABI < 1.0 Intermediate Slight or no modification 
ABI > 1.0 High Increase binder content 
ABI  >> 1* Very high Change formulation 
*ABI >> 1 when no granules on sieve and ABI = 0 when there is zero dust formation 
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Table 6. Disintegration time results and categorical responses. 
Compound 
Time to 
Disintegrate (min) 
Categorical 
Response 
Remarks 
Ibuprofen Grade 40 30 More than 5 min Dispersion of lumps 
Ibuprofen-PVP 25 % sol. 5 Less than 5 min Film disintegration 
Ibuprofen-sorbitol 60 % sol. 5 Less than 5 min Granule disintegration 
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Highlights 
 A novel approach for structural control of particulates is presented. 
 Effectiveness of process for granulation was evaluated. 
 Exceptionally narrow granule size distribution is achieved. 
 Granules exhibit slow irreversible deformation, low friability, good flowability and 
ease of disintegration. 
 
Graphical abstract 
From CAD model (a) to 3D Print (b), silicone mould (c), granulation (d), and characterisation (e)  
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